NASDAQ: SKYESkye Bioscience Inc Stock
$0.73-0.06 (-7.59%)
Updated Jun 15, 2026
SKYE Price
$0.73
Fair Value Price
$0.14
Market Cap
$25.65M
52 Week Low
$0.57
52 Week High
$5.75
P/E
-0.51x
P/B
2.85x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$57.33M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.16
Operating Cash Flow
-$42M
Beta
153.3
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
SKYE Overview
Skye Bioscience, Inc. is a biopharmaceutical firm focused on the discovery, development, and commercialization of cannabinoid-based therapeutics, primarily targeting various ophthalmic conditions. The company's leading drug candidate, SBI-100, is currently undergoing Phase I clinical trials for the treatment of glaucoma and ocular hypertension. In addition, Skye Bioscience is developing SBI-200, which is in preclinical stages, to manage and treat a spectrum of eye diseases such as uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. The company, originally named Emerald Bioscience, Inc., rebranded to Skye Bioscience, Inc. in January 2021. Founded in 2012, its headquarters are situated in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SKYE's potential to beat the market
- SKYE doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SKYE
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.59 | A | |
| $53.00 | A | |
| $16.00 | A |
Be the first to know about important SKYE news, forecast changes, insider trades & much more!
SKYE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SKYE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SKYE ($0.73) is overvalued by 416.22% relative to our estimate of its Fair Value price of $0.14 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SKYE ($0.73) is not significantly undervalued (416.22%) relative to our estimate of its Fair Value price of $0.14 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SKYE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SKYE due diligence checks available for Premium users.
Valuation
SKYE fair value
Fair Value of SKYE stock based on Discounted Cash Flow (DCF)
Price
$0.73
Fair Value
$0.14
Overvalued by
416.22%
SKYE ($0.73) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SKYE ($0.73) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SKYE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SKYE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.51x
Industry
16.41x
Market
14.3x
SKYE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.85x
Industry
4.89x
SKYE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SKYE's financial health
Profit margin
Revenue
$0.0
Net Income
-$12.5M
Profit Margin
0%
SKYE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$19.4M
Liabilities
$10.4M
Debt to equity
1.16
SKYE's short-term assets ($18.57M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SKYE's short-term assets ($18.57M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SKYE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SKYE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.6M
Investing
$10.9M
Financing
-$71.5k
SKYE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SKYE vs Biotech Stocks
Skye Bioscience Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.